PHOENIX, AZ--(MARKET WIRE)--Jun 29, 2007 -- Medistem Laboratories (OTC BB:MDSM.OB - News) (Frankfurt:S2U.F - News) announced today preclinical proof-of-concept studies demonstrating the positive potential of the company’s MDS-786 candidate drug for lung cancer. The findings were presented at the 13th Annual Meeting of the International Society for Cellular Therapy that took place June 24-27, 2007 in Sydney, Australia. The presentation, entitled “Differentiation and Inhibition of Tumor Cells by Cord Blood Stem Cells” reviewed the ability of MDS-786 to induce a process called “differentiation” in which tumor cells are coaxed into transforming into non-tumor cells through the use of a placentally derived product.
